OncoMed Pharma (OMED) Misses Q2 EPS by 10c

OncoMed Pharma (NASDAQ: OMED) reported Q2 EPS of ($0.91), $0.10 worse than the analyst estimate of ($0.81). Revenue for the quarter came in at $6.7 million versus the consensus estimate of $8.09 million.

For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• ACRES Commercial Realty says labor dispute is hindering hotel sale
• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth